Skip to main content
Home
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
      • Allergy & Asthma
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
    • Core Facilities
    • Lab Protocols
      • ITN Protocols
      • T1D Preclinical Consortium
    • Policies
      • Publications Policy
    • Proposals
      • Submit Proposal
      • Current RFPs
      • Past RFPs
    • Publications
    • TrialShare
    • Strategic Plans
      • Allergy
      • Autoimmune Disease
        • Type 1 Diabetes
      • Transplantation
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
      • Kidney
      • Liver
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
      • BRI - Seattle Office
      • UCSF - San Francisco Office
    • Media Inquiries
Home

Secondary links

  • Home
  • TrialShare
  • Member Portal
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
    • Core Facilities
    • Lab Protocols
    • Policies
    • Proposals
    • Publications
    • TrialShare
    • Strategic Plans
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
    • Media Inquiries

Primary links (clinical trials)

  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
      • Allergy & Asthma
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
    • Core Facilities
    • Lab Protocols
      • ITN Protocols
      • T1D Preclinical Consortium
    • Policies
      • Publications Policy
    • Proposals
      • Submit Proposal
      • Current RFPs
      • Past RFPs
    • Publications
    • TrialShare
    • Strategic Plans
      • Allergy
      • Autoimmune Disease
      • Transplantation
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
      • Kidney
      • Liver
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
      • BRI - Seattle Office
      • UCSF - San Francisco Office
    • Media Inquiries

Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered with Omalizumab, an anti-IgE Monoclonal Antibody

Principal Investigator

Thomas B. Casale | Creighton University School of Medicine | Omaha, NE

Locations

Creighton University Medical School | Omaha, NE
University of Wisconsin | Madison WI
University of Iowa | Iowa City, IA

Study Code

ITN019AD

Study Status

Completed

Abstract

Current therapies for seasonal allergic rhinitis (SAR) include allergen avoidance, pharmacologic interventions such as antihistamines, sympathomimetics, topical and systemic corticosteroids, and chromones and immunotherapy. Although pharmacologic agents are effective for some patients, their role is limited by their inability to completely relieve symptoms and, in some cases, the induction of deleterious side effects. Immunotherapy (IT) regimens can be highly effective in controlling symptoms of SAR and can offer advantages over pharmacotherapy for those patients who have symptoms that are refractory to medications or those who cannot tolerate the side effects. However, traditional IT is associated with the risk of allergic reactions to the extract injections and its effectiveness for allergic respiratory disorders is not always evident.

Allergic diseases are mediated by IgE and Th2-type immune responses, which are opposed by Th1-like responses. Omalizumab (anti-IgE) reduces IgE levels thereby leading to decreased FcER1 and CD23 expression on key immune effector cells. These and other changes evoked by omalizumab cause a blunting of allergic respiratory symptoms. In a recent clinical trial, the combination of omalizumab + IT produced a greater reduction in symptoms than IT alone. However, the omalizumab was added to existing IT. This study will examine omalizumab as a pretreatment to IT to condition the recipient in an attempt to suppress Th2-like responses.

Specifically, this study will:

  1. Examine whether anti-IgE (omalizumab) given 9 weeks prior to rush IT (RIT) followed by 12 weeks of dual anti-IgE + IT is safer and more effective than anti-IgE alone, RIT alone or placebo in preventing the symptoms of ragweed-induced SAR
  2. Study the immunologic mechanisms of action associated with these therapies
  3. Study whether there is induction of tolerance after discontinuing these therapies as manifested by persistent inhibition of in vivo challenges and prolonged in vitro immunologic changes indicative of immune tolerance
[Clinicaltrials.gov]

Principal Investigator

Thomas B. Casale | Creighton University School of Medicine | Omaha, NE

Locations

Creighton University Medical School | Omaha, NE
University of Wisconsin | Madison WI
University of Iowa | Iowa City, IA

Articles

Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, Francis JN, Immune Tolerance Network Group. (2007) Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol, 120 (3), 688-95. PMID: 17631952 [PubMed] [Reprint]
Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Deniz Y, Immune Tolerance Network. (2006) Omalizumab pretreatment decreases acute reactions following rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol, 117 (1), 134-140. PMID: 16387596 [PubMed] [Reprint]

The Immune Tolerance Network and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

National Institute of Allergy and Infectious Diseases

Footer

  • Home
  • Sponsors
  • Careers
  • Contact
  • Search

© 2021 Immune Tolerance Network

  • Privacy
  • Terms of Use
  • Accessibility